Abstract | CONTEXT: OBJECTIVE: The aims of this study were to evaluate the dose range, side effects, and long-term follow-up of octreotide therapy in a large cohort of CHI patients. SETTING: The study was conducted at an international referral center for the management of CHI. PATIENTS: MAIN OUTCOME MEASURES: Regular follow-up of auxology, growth factors (serum IGF-1 and IGF binding protein 3 levels), thyroid functions, liver function tests, and hepatobiliary ultrasonography were measured. RESULTS: The median age of CHI diagnosis was 1 week (range 1-80 wk). The mean (±SD) dose of octreotide required was 17.8 (±7.5) μg/kg · d (range 7.5-30 μg/kg · d). The mean (±SD) duration of follow-up on octreotide therapy was 52.4 (±33.8) months (range 6 mo to 9.5 y). Elevation of liver enzymes was the most prevalent side effect (n = 13; 46.4%), which resolved spontaneously. Gallbladder pathology was detected in nine patients (32%). Mean (±SD) duration of octreotide therapy before the development of gallbladder pathology was 4.3 (±4.6 mo), whereas 19 patients were free of gallstones after a follow-up of 53.6 ± 32.9 months on octreotide therapy. There was no relationship between the dose or the duration of octreotide therapy and development of gallbladder pathology or liver dysfunction. CONCLUSIONS:
|
Authors | Huseyin Demirbilek, Pratik Shah, Ved Bhushan Arya, Louise Hinchey, Sarah E Flanagan, Sian Ellard, Khalid Hussain |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 99
Issue 10
Pg. 3660-7
(Oct 2014)
ISSN: 1945-7197 [Electronic] United States |
PMID | 24937539
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Insulin-Like Growth Factor I
- Thyroxine
- Octreotide
|
Topics |
- Age of Onset
- Antineoplastic Agents, Hormonal
(administration & dosage, adverse effects)
- Child
- Child, Preschool
- Congenital Hyperinsulinism
(drug therapy, genetics, metabolism)
- Female
- Follow-Up Studies
- Humans
- Infant
- Infant, Newborn
- Insulin-Like Growth Factor I
(metabolism)
- Male
- Octreotide
(administration & dosage, adverse effects)
- Thyroxine
(blood)
- Time
- Treatment Outcome
|